特立帕肽前抗骨质疏松治疗与骨折相关住院风险
本研究基于台湾健保数据库14,770例极高骨折风险患者,评估特立帕肽前抗骨质疏松药物(AOM)使用对骨折相关住院的影响。结果显示AOM总体不增加骨折相关住院风险,但长期使用地舒单抗(≥3年)后换用特立帕肽与脊柱骨折相关住院风险升高相关。
要点
- 特立帕肽前使用AOM总体不增加骨折相关住院风险。
- 双膦酸盐使用与骨折及脊柱骨折相关住院风险降低相关。
- 地舒单抗≥3年者换用特立帕肽后脊柱骨折相关住院风险显著升高。
核心结论
- 在极高骨折风险患者中,特立帕肽前使用AOM与骨折相关住院风险增加无关。
- 但特立帕肽前长期使用地舒单抗(≥3年)与脊柱骨折相关住院风险升高相关。
研究设计与样本
- 全国性队列研究,使用台湾全民健康保险研究数据库(2013-2019年),纳入14,770例极高骨折风险患者。
- 按既往AOM使用(是vs否)、AOM类型(双膦酸盐vs地舒单抗vs雷洛昔芬;地舒单抗vs非地舒单抗)及地舒单抗使用时长(≥3年vs<3年)分组。
- 主要结局为3年内主要骨质疏松性骨折相关住院。
主要发现
- 9,127例在特立帕肽开始前2年内接受AOM治疗,5,643例未接受。
- AOM组与非AOM组骨折相关住院无统计学显著差异(HR=0.92;95%CI 0.83-1.02;p=0.102)。
- AOM治疗组脊柱骨折相关住院HR较低(HR=0.85;95%CI 0.73-0.98;p=0.026)。
- 双膦酸盐与骨折相关住院降低相关(HR=0.85,95%CI 0.75-0.96),与脊柱骨折相关住院降低相关(HR=0.83,95%CI 0.76-0.91)。
- 地舒单抗使用≥3年后换用特立帕肽者脊柱骨折相关住院风险显著升高(校正HR=1.86,p=0.011),转换后前6个月内尤为明显(校正HR=1.98,p=0.031)。
关键数值与推荐
- AOM组与非AOM组骨折相关住院:HR=0.92(95%CI 0.83-1.02;p=0.102)。
- AOM组脊柱骨折相关住院:HR=0.85(95%CI 0.73-0.98;p=0.026)。
- 双膦酸盐与骨折相关住院:HR=0.85(95%CI 0.75-0.96);与脊柱骨折相关住院:HR=0.83(95%CI 0.76-0.91)。
- 地舒单抗≥3年者换用特立帕肽后脊柱骨折相关住院:校正HR=1.86(p=0.011);转换后前6个月:校正HR=1.98(p=0.031)。
临床怎么用
- 对极高骨折风险患者启动特立帕肽前,应评估既往AOM类型及疗程,尤其关注地舒单抗使用时长。
- 长期地舒单抗(≥3年)治疗者换用特立帕肽时,需警惕脊柱骨折风险,尤其转换后前6个月。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: This study evaluated whether prior anti-osteoporosis medication (AOM) use influences fracture risk in patients at very high fracture risk who subsequently initiated teriparatide. Using a nationwide cohort of 14,770 patients, participants were categorized based on prior AOM exposure. Bisphosphonate was associated with decreased both fracture and spinal fracture-related hospitalization, while the decreased risk was not shown in denosumab users. Long-term denosumab use (≥ 3 years) was associated with a significantly increased risk of spine fracture-related hospitalization after transitioning to teriparatide. PURPOSE: To evaluate whether prior AOM use, including type and duration, affects fracture-related hospitalization in patients at very high fracture risk initiating teriparatide. METHODS: This nationwide cohort study used Taiwan's National Health Insurance Research Database (2013-2019) to examine 14,770 patients. Patients were categorized by prior AOM use (yes vs no), AOM type (bisphosphonates vs denosumab vs raloxifene; denosumab vs non-denosumab), and denosumab duration (≥ 3 vs < 3 years). The primary outcome was hospitalization for major osteoporotic fractures within 3 years. RESULTS: 9,127 participants received AOM treatment within 2 years prior to teriparatide initiation, whereas 5,643 did not. There was no statistically significant difference in fracture-related hospitalizations between the AOM and non-AOM groups (HR = 0.92; 95% CI 0.83-1.02; p = 0.102). However, the HR for spinal fracture-related hospitalization was lower in the AOM treatment group (HR = 0.85; CI 0.73 to 0.98; p = 0.026).] Bisphosphonate was associated with decreased both fracture and spinal fracture-related hospitalization, (HR = 0.85, 95% CI = 0.75-0.96 for fracture; HR = 0.83, 95% CI = 0.76-0.91 for spinal fracture), while the decreased risk was not shown in denosumab users. Noteworthy, patients who had used denosumab for ≥ 3 years before switching to teriparatide had a significantly higher risk of spine fracture--related hospitalizations (adjusted HR 1.86, p = 0.011), particularly within the first 6 months of transitioning (adjusted HR 1.98, p = 0.031). CONCLUSION: Prior AOM therapy was not associated with an increased fracture-related hospitalization risk after starting teriparatide in patients at very high fracture risk. However, among those who used AOM before teriparatide initiation, long-term denosumab use (≥ 3 years) was associated with an increased risk of spine fracture-related hospitalization. Further research is warranted to optimize sequential therapy strategies among patients under long-term denosumab use.
引用
- Fu SC, Lu YC, Sie NH, et al. Pre-teriparatide anti-osteoporosis medication therapy and fracture-related hospitalization in patients at very high fracture risk. Osteoporos Int. 2026. PMID: 42228020. doi:10.1007/s00198-026-08081-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。